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Abstract 
Drug targeting via lipoproteins may be of benefit for use of cytotoxic drugs like fluorothymidine (FLT) or azidothymidine (AZT). 
Both drugs are potent inhibitors of the human immunodeficiency virus (HIV) reverse transcriptase and are used in the therapy of HIV 
infection. With regard to this project, the selective ndocytosis n HIV infected human macrophages was studied after covalent coupling 
of AZT and LDL to low density lipoproteins (LDL). Cultured human macrophages and the lymphocytic Molt 4/8 cell line were infected 
with H1V-1 in vitro and subsequently treated with FLT-LDL or AZT-LDL. Viral replication was followed by determination of 
cell-released capsid antigen p24. Internalisation i to HIV-1 infected human macrophages by the scavenger receptor pathway leads to a 
dose dependent inhibition of H1V replication. Otherwise, in HIV infected, but scavenger receptor missing lymphocytes (Molt 4/8 cells), 
neither endocytosis nor inhibition of HIV replication results. Thus, covalent coupling of drugs to LDL leads to a macrophage specific 
transport. This strategy could possibly avoid toxic side effects in the therapeutic use of antiretroviral drugs and thus may open a way for 
an earlier chemotherapy in HIV infection. 
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I. Introduction 
Apolipoproteins play an essential role in receptor medi- 
ated uptake of lipoprotein particles into target cells. Low 
density lipoproteins (LDL) contain apolipoprotein B100 
(apoB), a strongly basic protein due to more than 300 
lysine residues. LDL is intemalised via the LDL receptor 
pathway in virtually every human cell. 
Native LDL is cleared from the plasma through a 
regulated pathway by binding to the apo B /E  receptors 
present in hepatocytes followed by endocytosis. Further- 
more, chemically modified LDL particles are taken up by 
macrophages via a specific receptor system [1,2]. Hence, 
glucosylation, aldehyde derivatisation and oxidation, alter 
the cellular specificity of LDL uptake. The macrophage 
specific cell surface proteins which mediate the internalisa- 
tion of modified LDL are the scavenger receptors [3,4]. 
Specifity of scavenger receptor mediated uptake was eval- 
* Corresponding author. Fax: +49 30 8382936. 
uated by a number of studies using acetylated LDL in 
competition experiments [3,5]. 
Derivatisation of the lysine epsilon amino groups of the 
apoB-protein abolishes binding of apoB to the LDL recep- 
tor and initiates the affinity to the scavenger eceptor 
[6-9]. 
As previously described [10] covalent coupling of 
thymidine as model for nucleoside and nucleoside-ana- 
logues to the lysine side chain of apoB results in a 
LDL-nucleoside complex, which is specifically inter- 
nalised by macrophages, but not by hepatocytes, which 
lack scavenger receptors. Since the coupling reaction seems 
not to affect the structure of LDL, endocytosis of thymi- 
dine-LDL is similar to that of naturally occurring modified 
LDL. Degradation of the thymidine-LDL complex released 
thymidine in a biologically active form as shown by 
incorporation of radioactive labelled thymidine into the 
cellular DNA [11]. This receptor pathway may be applied 
for targeted delivery of drugs used for the therapy of 
macrophage associated iseases [10]. The specifity of LDL 
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uptake in lymphocytes and monocytes derived from HIV 
infected donors was confirmed recently [12]. In this study, 
f luorothymidine and azidothymidine were covalently cou- 
pled to LDL. The selective endocytosis of FLT-LDL and 
AZT-LDL  into HIV infected cultured human macrophages 
was compared to scavenger receptor missing lymphocytes 
(Molt 4 /8  cell line). 
1 2 3 
Fig. 1. Separation of native and modified LDL by agarose gel elec- 
trophoresis. LDL was prepared from human blood plasma by KBr density 
gradient ultracentrifugation. The LDL fraction (d = 1.019-1.063 g/cm 3) 
was dialysed against standard buffer. Modification of LDL was done by 
covalent coupling of AZT or FLT. Lane 1: native LDL, lane 2: FLT-LDL, 
lane 3." AZT-LDL. 
2. Materials and methods 
2.1. Preparation of  low density lipoproteins 
LDL was prepared from plasma from healthy blood 
donors by KBr density gradient centrifugation as described 
earlier [9]. LDL fractions (d  = 1.019-1.063 g /cm 3) were 
dialysed against standard buffer (0.15 M NaCI, 0.5 mM 
EDTA, pH 7.4, 4°C). 
2.2. Coupling of  FLT and AZT 
Step I: 4-nitrophenyl-f luorothymidine-carbonate was 
prepared from 70 mg 4-nitrophenyl-chloroformic a id 
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Fig. 2. Comparison of FLT-LDL and FLT treatment of HIV-1 infected cultured human macrophages. Macrophages were derived from peripheral blood 
monocytes of healthy human donors after adherence s lection to plastic dishes. Cultured macrophages were washed extensively to remove contaminating 
lymphocytes. Cells were infected with HIV-1 followed by extensive washing after 24 h and subsequently reated with different concentrations of FLT-LDL 
or free FLT, including an untreated control. Viral replication was followed by determination f cell released capsid antigen p24. The results are mean of 3 
independent experiments. 
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(Sigma) and 50 mg 3'-deoxy-3'-fluorothymidine by 60 min 
incubation in 20 ml dry dioxane with 2 mg dimeth- 
ylaminopyridine at 80°C under nitrogen, evaporating in 2 
ml methanol/acetone (1:1) and purification over a silica 
gel G60 column. 
Step II: Coupling of 4-nitrophenyl-fluorothymidine- 
carbonate to the apoB moiety of LDL comprises tepwise 
addition of 10 mg 4-nitrophenyl-fluorothymidine-carbonate 
(in 125/zl methanol) to LDL (10 mg LDL-protein) in 1 ml 
phosphate buffer (250 mM, pH 10.0) and 30 min stirring at 
4°C. FLT-LDL was purified by Sephadex gel chromatogra- 
phy (Sephadex G75). 
AZT-LDL was prepared as above using AZT instead of 
FLT. The coupling ratio of chemical bound nucleosides 
obtained by this method is 300 molecules nucleoside per 
LDL particle based upon spectrophotometric analysis 
(Mankertz et al., submitted) and agarose gel electrophore- 
sis. 
2.4. Antiviral assay 
Human monocytes/macrophages w re isolated from 
huffy coat by ficoll gradient centrifugation and adherence 
to plastic petri dishes within 6-8 days. Adhering cells 
were washed extensively with phosphate buffered saline to 
remove contaminating T cells and subsequently infected 
with HIV-1 strain IIIB at a multiplicity of infection of 
0.2-0.3 followed by extensive washing after 24 h. Molt 
4 /8  cells, a CD4 + T cell line was infected with HIV-1 as 
before, but virus was removed by washing after 2 h. Cells 
were treated with various concentrations (0.16/xM to 4.00 
/zM) of either FLT-LDL or AZT-LDL 24 h (macrophages) 
or 2 h (Molt 4/8 cells) after infection, including an 
untreated control. Drug containing medium was changed 
every 2-3 days and cell culture supernatant was tested for 
HIV-1 p24 core antigen by enzyme linked immunosorbant 
assay (Coulter HIV-1 p24 antigen assay). 
2.3. Lipid gel electrophoresis 
Agarose lipoprotein electrophoresis was conducted with 
the Paragon Lipo Kit (Beckman) according to the instruc- 
tions of the manufacturer. 
3. Results 
FLT and AZT can be covalently coupled to LDL parti- 
cles. The derivatization of LDL with FLT or AZT lowers 
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Fig. 3. Comparison of FLT-LDL and FLT treatment of HIV-1 infected lymphocytic Molt 4 /8  cells. The lymphocytic cell line Molt 4 /8  was infected with 
HIV-1 followed by washing after 2 h. Subsequently, cells were  treated with different concentrations of FLT-LDL or free FLT, including an untreated 
control. Viral replication was followed by determination f cell released capsid antigen p24. The results are mean of 2 independent experiments. 
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the positive charge of LDL and therefore reduces its 
electrophoretic mobility compared to native LDL (Fig. 1). 
The correlation of chemical modification and reduced elec- 
tric charge allows an estimation of the degree of derivatisa- 
tion by agarose gel electrophoresis. Furthermore, the num- 
ber of covalently coupled ligands can be estimated by UV 
spectrophotometric methods (Mankertz, submitted). Fully 
derivatised LDL particles contain about 300 nucleoside 
molecules per LDL particle. The slight difference in migra- 
tion can be explained by a different net charge of AZT 
compared to FLT. 
The effect of FLT-LDL and AZT-LDL on HIV-1 repli- 
cation in primary human macrophages was followed by 
HIV p24 core antigen determination i the cell culture 
supernatant. Treatment with free FLT was compared to 
LDL bound FLT on macrophage cultures derived from the 
same blood donor (Fig. 2). The concentration of the drug 
was 0.16 /xM to 4.00 ~M with respect o the nucleoside 
portion. The untreated control showed the typical HIV 
infection kinetics while the inhibition of viral replication 
by unbound FLT and FLT-LDL was dose dependent. 
Complete inhibition was seen after 15 days even at the 
lowest concentrations u ed without compromising cell via- 
bility. These results show that FLT becomes available to 
HIV-1 reverse transcriptase after uptake of the FLT-LDL 
complex. 
No inhibition of HIV-1 replication by FLT-LDL could 
be demonstrated in the lymphocytic Molt 4//8 cell line 
(Fig. 3). In contrast to free FLT, FLT-LDL had obviously 
no effect on viral replication in Molt 4//8 cells, which do 
not express scavenger receptors, whereas the addition of 
0.80 /xM free FLT to the cell culture medium abolished 
virus replication completely. Lower concentrations of free 
FLT (0.16 /xM) showed only weak effects, similar to the 
application of high amounts FLT-LDL (0.80 /zM with 
respect to the nucleoside portion). 
HIV replication in primary and cultured human periph- 
eral blood monocytes//macrophages can also be inhibited 
by AZT. To compare the effect of AZT-LDL and FLT-LDL 
treatment in the reduction of viral replication in cells of the 
monocyte//macrophage lin age, we incubated HIV-1 in- 
fected human macrophages derived from the same blood 
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Fig. 4. Comparison of FLT-LDL and AZT-LDL treatment of HIV-1 infected cultured human macrophages. Cultured human macrophages derived from 
human peripheral blood monocytes by adherence selection were infected with HIV-1 followed by extensive washing after 24 h and subsequently treated 
with different concentrations of FLT-LDL or AZT-LDL, including an untreated control. Viral replication was followed by determination f cell released 
capsid antigen p24. The results are mean of 3 independent experiments. 
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donor with increasing amounts of both substances (Fig. 4). 
The untreated control showed the typical release of p24 
core antigen, whereas AZT-LDL and FLT-LDL abolished 
viral replication completely even at the lowest concentra- 
tion after 15 days. There is no significant difference be- 
tween both derivatives in the degree of inhibition indicat- 
ing that FLT-LDL is as effective as AZT-LDL in the 
treatment of HIV infected monocytes/macrophages. 
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4. Discussion 
Macrophages, T-helper lymphocytes, and dendritic ells 
[13] are target cells for HIV. Macrophages infected with 
HIV are considered as reservoirs for virus spread [13-16]. 
Antiretroviral drugs like AZT [17] can cause severe toxic 
side effects. Hence, improvement of antiretroviral therapy 
may arise by using cell specific application [18,19]. 
The scavenger eceptor plays a key role in the 
metabolism of naturally occurring modified LDL particles 
such as malondialdehyde-LDL and 4-hydroxynonal- 
dehyde-LDL [8,20]. Therefore, specific uptake of other 
modified LDLs, like FLT-LDL and AZT-LDL, by cells of 
the macrophage lineage via the scavenger receptor in vivo 
may be anticipated. 
In our experiments we could demonstrate, that the 
spread of HIV in macrophage cell cultures was effectively 
inhibited by FLT and AZT coupled to LDL, showing the 
intracellular availability of the drugs. HIV infection in 
Molt 4 /8  cells (CD4 positive T-helper cells), which served 
as model for cells lacking scavenger receptors are not 
affected by FLT-LDL. The results show, that FLT, a more 
potent but more toxic inhibitor of HIV replication com- 
pared to AZT [21,22] can be covalently coupled to LDL. 
Incubation with FLT-LDL and AZT-LDL leads to a dose 
dependent inhibition of HIV replication in HIV infected 
cultured human macrophages but not in HIV infected 
lymphocytes. 
Cell specificity of AZT-LDL, FLT-LDL or other 
derivatised LDL particles for cells expressing scavenger 
receptors are pharmacological properties which may allow 
lower therapeutic doses and hence diminish bone marrow 
toxicity. Especially in the case of fluorothymidine, which 
showed toxic side effects in clinical trials [23], a cell 
specific transport via FLT-LDL particles may lead to a 
successful therapeutic use even in the early phase of viral 
infection. 
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